BICYCLE THERAPEUTICS CLOSES £40 MILLION ($52 MILLION) IN SERIES B FINANCING TO ADVANCE CLINICAL PIPELINE

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the successful completion of a £40 million Series B financing round. Proceeds will be used to further the development of multiple drug candidates, including Bicycle’s lead molecule, BT1718, a first-in-class drug for cancers of high unmet need.

Read More

BICYCLE THERAPEUTICS ANNOUNCES A CANDIDATE PRECLINICAL MILESTONE IN ITS OPHTHALMOLOGY ALLIANCE WITH THROMBOGENICS

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, today announced the receipt of a preclinical milestone in connection with the advancement of a Bicycle into preclinical development for the treatment of diabetic macular edema, under its ophthalmology alliance with ThromboGenics, a biopharmaceutical company focused on developing treatments for back of the eye disease.

Read More

BICYCLE THERAPEUTICS ANNOUNCES PRESENTATIONS AT THE 2017 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the company will present preclinical data supporting the ongoing development of its lead molecule, BT1718.

Read More

BICYCLE THERAPEUTICS IS NAMED WINNER OF BUSINESS WEEKLY’S DISRUPTIVE TECHNOLOGY AWARD 2017

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that it has been named by Business Weekly as the winner of its 2017 Disruptive Technology Award.

Read More

BICYCLE THERAPEUTICS TO PRESENT AT COWEN AND COMPANY 37TH ANNUAL HEALTH CARE CONFERENCE

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (BicycleTM) product platform, announced today that Kevin Lee, Ph.D., Bicycle’s Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference in Boston, MA.

Read More

BICYCLE THERAPEUTICS APPOINTS NICHOLAS KEEN, PH.D., AS CHIEF SCIENTIFIC OFFICER

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today the appointment of Nicholas Keen, Ph.D., as Chief Scientific Officer.

Read More

BICYCLE THERAPEUTICS IS NAMED WINNER OF FIERCE INNOVATION AWARD Bicycle Drug Conjugates® Take Top Prize for Drug Delivery Technology

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based
on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that it
has been selected by a panel of industry experts as the winner of the best Drug Delivery
Technology category in the Fierce Innovation Awards for Life Sciences 2016.

Read More

CANCER RESEARCH UK AND BICYCLE THERAPEUTICS COLLABORATE TO TRIAL NEW THERAPY FOR ADVANCED SOLID TUMOURS

Cancer Research UK, Cancer Research Technology (CRT), and Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, have today announced an agreement to trial a first-in-class drug for cancers of high unmet need.

Read More

BICYCLE THERAPEUTICS ANNOUNCES BROAD PARTNERSHIP WITH ASTRAZENECA TO DEVELOP BICYCLIC PEPTIDES (BICYCLES®)

Bicycle
Therapeutics, a biotechnology company pioneering a new class of therapeutics based
on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that it
has entered into a collaboration with AstraZeneca for the identification and development
of bicyclic peptides (Bicycles®) for the treatment of respiratory, cardiovascular and
metabolic diseases.

Read More

 

BICYCLE THERAPEUTICS TO PRESENT PRECLINICAL DATA AT THE 28th EORTC-NCI-AACR MOLECULAR TARGETS AND CANCER THERAPEUTICS SYMPOSIUM

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that the company will present preclinical data highlighting the development of its lead molecule BT1718.

Read More

BICYCLE THERAPEUTICS APPOINTS PETER U. PARK, PH.D., AS VICE PRESIDENT OF ONCOLOGY RESEARCH

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) product platform, announced today the appointment of Peter U. Park, Ph.D., as Vice President of Oncology Research in its Cambridge, MA office.

Read More

BICYCLE THERAPEUTICS APPOINTS STEPHEN J. HOFFMAN, M.D., PH.D., AS BOARD CHAIRMAN

CAMBRIDGE, MASS. and CAMBRIDGE, U.K. – July 18, 2016 – Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles®) platform, announced today the appointment of Stephen J. Hoffman, M.D., Ph.D., as Chairman of the Board of Directors. 

Read More

Bicycle Therapeutics establishes US Operations and appoints Rosamond Deegan, MBA, as President and Chief Business Officer

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles®) platform, announced today it has established U.S. operations with headquarters in Cambridge, Massachusetts and named Rosamond Deegan, MBA, as President and Chief Business Officer. In this newly created role, Ms. Deegan will be responsible for leading Bicycle Therapeutics’ business development activities and establishing a U.S. team aligned with the Company’s focus on oncology clinical development.

Read More

Bicycle Therapeutics strengthens product development capabilities with key leadership appointments

Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptides (Bicycles®) technology, announced today that it has strengthened its global management team to enhance its drug discovery and product development capabilities as the Company progresses toward clinical testing.

Read More

Bicycle Therapeutics announces appointment of CEO

Bicycle Therapeutics, a biotechnology company developing a new therapeutic modality based on bicyclic peptides, today announced the appointment of Kevin Lee, Ph.D., as Chief Executive Officer. Dr. Lee brings more than 20 years of experience in drug discovery and development leadership, most recently from Pfizer, spanning the pharmaceutical and biotechnology industries as well as academia.

Read More

Bicycle Therapeutics announces £20M ($32M) million financing for drug development

Bicycle Therapeutics, a next generation biotherapeutics company developing first-in-class bicyclic peptides, today announced that it had secured an equity financing of £20 ($32M) million for the clinical development of therapeutic bicycle drug candidates in oncology.

Read More